<DOC>
	<DOC>NCT00654602</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy and safety of rosuvastatin in reducing low density lipoprotein cholesterol levels to internationally recognised goals in subjects with dyslipidaemia.</brief_summary>
	<brief_title>48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Lipid Regulating Agents</mesh_term>
	<criteria>Fasting low density lipoprotein level as defined by the protocol. Fasting triglyceride level as defined by the protocol. The use of lipid lowering drugs or dietary supplements after Visit 1. Active arterial disease eg Unstable angina, or recent arterial surgery. Blood lipid levels above the limits defined in the protocol. Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>cholesterol</keyword>
	<keyword>low density lipoproteins</keyword>
	<keyword>dyslipidaemia</keyword>
	<keyword>Rosuvastatin</keyword>
	<keyword>Crestor</keyword>
</DOC>